Ovid Therapeutics has been granted a patent for methods of treating various conditions including tinnitus, hearing loss, Meniere’s disease, Tourette’s syndrome, ADHD, and addiction. The patent claims the use of specific compounds to alleviate symptoms such as aural fullness or hearing loss in patients without tinnitus. Therapeutic compositions are also mentioned. GlobalData’s report on Ovid Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ovid Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Ovid Therapeutics's grant share as of September 2023 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11771671B2) describes a method for treating aural fullness or hearing loss associated with sudden sensorineural hearing loss. The method involves administering a specific compound, (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof, to patients who do not have tinnitus. The compound is administered in a dosage ranging from 0.01 mg to 500 mg, and it effectively alleviates the symptoms of aural fullness or hearing loss.
According to the patent claims, the improvement in symptoms lasts for more than 6 hours after administration. The patient can be administered a composition containing 1 mg to 100 mg of the compound or a salt thereof, or a composition containing 25 mg to 80 mg of the compound or a salt thereof. The total amount of the compound or salt administered in a 24-hour period can range from 1 mg to 500 mg. The compound can be administered from one to four times a day via various routes such as oral, buccal, sublingual, rectal, topical, intranasal, vaginal, or parenteral.
Additionally, the patent also describes an alternative compound, (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, or a pharmaceutically acceptable salt thereof, for treating aural fullness or hearing loss associated with sudden sensorineural hearing loss. The dosage for this compound ranges from 0.01 mg to 75 mg, and it effectively alleviates the symptoms. The patient can be administered 0.1 mg to 50 mg of the compound or salt thereof, or 0.1 mg to 10 mg of the compound or salt thereof. The total amount administered in a 24-hour period can range from 1 mg to 10 mg. Similar to the previous compound, this compound can also be administered from one to four times a day via various routes.
In summary, the granted patent describes methods for treating aural fullness or hearing loss associated with sudden sensorineural hearing loss using specific compounds or their pharmaceutically acceptable salts. These compounds effectively alleviate the symptoms when administered within the specified dosage ranges. The patent provides flexibility in terms of dosage, frequency of administration, and routes of administration, allowing for personalized treatment approaches.
To know more about GlobalData’s detailed insights on Ovid Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
